Evidence map›Paper›PMID 30745571›Full record

ArticlePediatric research2019

Urinary acute kidney injury biomarkers in very low-birth-weight infants on indomethacin for patent ductus arteriosus.

Sina Waldherr, Alexander Fichtner, Bernd Beedgen, Thomas Bruckner, Franz Schaefer, Burkhard Tönshoff, Johannes Pöschl, Timm H Westhoff, Jens H Westhoff

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Article
  8. Article
  9. Observational
  10. Gut microbiota and neonatal acute kidney injury biomarkers.Pediatric nephrology (Berlin, Germany) · 2023
    Review
  11. Article
  12. Review
  13. Observational
  14. Article
  15. Urinary NMR Profiling in Pediatric Acute Kidney Injury-A Pilot Study.International journal of molecular sciences · 2020
    Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sina WaldherrDepartment of Neonatology, University Children's Hospital, Heidelberg, Germany.
Alexander FichtnerDepartment of Pediatrics I, University Children's Hospital, Heidelberg, Germany.
Bernd BeedgenDepartment of Neonatology, University Children's Hospital, Heidelberg, Germany.
Thomas BrucknerInstitute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
Franz SchaeferDepartment of Pediatrics I, University Children's Hospital, Heidelberg, Germany.
Burkhard TönshoffDepartment of Pediatrics I, University Children's Hospital, Heidelberg, Germany.
Johannes PöschlDepartment of Neonatology, University Children's Hospital, Heidelberg, Germany.
Timm H WesthoffMedical Department I, Marien Hospital Herne, University Hospital of the Ruhr-University of Bochum, Herne, Germany.
Jens H WesthoffDepartment of Pediatrics I, University Children's Hospital, Heidelberg, Germany. jens.westhoff@med.uni-heidelberg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSerum creatinine (SCr)- or urine output-based definitions of acute kidney injury (AKI) have important limitations in neonates. This study evaluates the diagnostic value of urinary biomarkers in very low-birth-weight (VLBW) infants receiving indomethacin for closure of a patent ductus arteriosus (PDA).

methodsProspective cohort study in 14 indomethacin-treated VLBW infants and 18 VLBW infants without indomethacin as controls. Urinary biomarkers were measured before, during, and after indomethacin administration.

resultsIndomethacin therapy was associated with significantly higher SCr concentrations at 36, 84, and 120 h compared to controls. At 36 h, three indomethacin-treated patients met the criteria for neonatal modified Kidney Disease: Improving Global Outcomes (KDIGO) AKI. The product of urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 ([TIMP-2]•[IGFBP7]) was significantly elevated in the AKI subgroup at 12 h (P < 0.05), hence 24 h earlier than the increase in SCr. Urinary neutrophil gelatinase-associated lipocalin (NGAL) and calprotectin were significantly increased in the indomethacin group at 12 h (P < 0.05), irrespective of fulfillment of the AKI criteria. Urinary kidney injury molecule-1 (KIM-1) was not significantly altered.

conclusionWhile urinary [TIMP-2]•[IGFBP7] proves valuable for the early diagnosis of neonatal modified KDIGO-defined AKI, elevated urinary NGAL and calprotectin concentrations in indomethacin-treated VLBW infants not fulfilling the AKI criteria may indicate subclinical kidney injury.

Indexed as

Acute Kidney InjuryBiomarkersCardiovascular AgentsCase-Control StudiesCreatinineCross-Sectional StudiesDuctus Arteriosus, PatentFemaleHumansIndomethacinInfant, Low Birth WeightInfant, NewbornInfant, Very Low Birth WeightInsulin-Like Growth Factor Binding ProteinsLeukocyte L1 Antigen ComplexLipocalin-2BiomarkersCardiovascular AgentsCreatinineIndomethacininsulin-like growth factor binding protein-related protein 1Insulin-Like Growth Factor Binding ProteinsLCN2 protein, humanLeukocyte L1 Antigen ComplexLipocalin-2TIMP2 protein, humanTissue Inhibitor of Metalloproteinase-2

Identifiers

PMID30745571

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.